Atopic Dermatitis Treatment Market

Key Factors Shaping the Atopic Dermatitis Treatment Market

• Launch of Topical Non-corticosteroid Immunomodulation for Atopic Dermatitis Treatment

  Corticosteroids remain highly preferred drugs for inflammatory diseases like atopic dermatitis treatment, as they act effectively in short duration. However, the long-term use of corticosteroids is associated with skin atrophy and other complications.

  One of the key factors shaping the atopic dermatitis treatment market is the launch of two topical non-corticosteroid immunomodulators – Tacrolimus and Pimecrolimus – which have promising results in long term, when used in monotherapy compared with combination with corticosteroids.

• Targeted Biologic Therapeutics in Atopic Dermatitis Treatment

  Dupilumab is a monoclonal antibody, developing as the first line therapeutic for moderate to serious atopic dermatitis. Dupilumab received approval from the US Food and Drug Administration (FDA) in 2017 for adults with moderate-to-extreme atopic dermatitis which cannot be sufficiently controlled by topical treatment. In 2019, this indication was extended to include adolescent 12 years or older. It is a subcutaneous infusion administered at regular every 2 weeks intervals.

• Industry Consolidations Lead to Faster Time-to-Market

  Key players of the atopic dermatitis treatment market are primarily focused on joint venture and partnership with other local players for the development of novel products. The parent organization can use the latter’s clinical improvement expertise and regulatory knowledge to ensure a success circumstance in such associations. Numerous organizations are focusing on expanding their product portfolio by procuring products from the acquired company.

• High Growth Prospects in Developing Economies

  Increase investments in the healthcare domain, developing healthcare infrastructure, and increasing prevalence of atopic dermatitis in Asia Pacific region are factors offering a strong impetus to the growth of atopic dermatitis treatment market.

  The launch of better therapeutic drugs prominently accounts for the growing popularity of atopic dermatitis treatment across developing regional markets. Consistent rise in the number of manufacturers and distributors in the region is likely to contribute to the growth of the atopic dermatitis treatment market in the near future.

Atopic Dermatitis Treatment Competition Analysis

• Key players continue to increase the market share with the launch of new products in the market.
• Joint ventures and partnership with distributors are the strategic actions practised by majority of key players.
• Prominent players continue to address the unmet needs in the market through inorganic strategies, such as mergers and acquisitions.
• The atopic dermatitis treatment market has been relatively moderate in size and likely to remain dynamic, growing in steady pace throughout the forecast period.
• Major players focus on inorganic growth strategy to make a strong hold on targeted in-licensing and acquisitions through expanding its R&D activities and its distribution channels particularly including its specialist retail chains.

Atopic Dermatitis Treatment: Segmentation

Drug Class

• Corticosteroids
• Calcineurin Inhibitors
• Immunosuppressants
• Biologic Therapy
• PDE-4 Inhibitor
• Antibiotics
• Antihistamines
• Emollients

Mode of Administration

• Topical
• Oral
• Injectable

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Mail Order Pharmacies
• Dermatology Clinics

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific excluding Japan
• Japan
• Middle East & Africa